Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Patent
1995-06-07
1997-12-02
Feisee, Lila
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
53038822, 4241331, 4241431, A61K 39395
Patent
active
056937628
ABSTRACT:
Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about about 3 .ANG. as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria. When combined into an intact antibody, the humanized immunoglobulins of the present invention will be substantially non-immunogenic in humans and retain substantially the same affinity as the donor immunoglobulin to the antigen, such as a protein or other compound containing an epitope.
REFERENCES:
patent: 4578335 (1986-03-01), Urdal et al.
patent: 4816397 (1989-03-01), Boss et al.
patent: 4816565 (1989-03-01), Honjo et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4845198 (1989-07-01), Urdal et al.
patent: 4867973 (1989-09-01), Goers et al.
patent: 5198359 (1993-03-01), Taniguchi et al.
patent: 5225539 (1993-07-01), Winter
patent: 5476786 (1995-12-01), Huston et al.
Groves et al. Hybridoma vol. 6 (1) 1987 71.
Chothia, C. and Lesk, A.M., "Canonical Structures for the Hypervariable Regions of Immunoglobulins," J. Mol. Biol., 196:901-917 (1987).
Jones et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse," Nature, 321:522-525 (1986).
Junghans et al., Cancer Res., 50:1495-1502 (1990).
Kupiec-Weglinski et al., Proc. Natl. Acad. Sci., 83:2624 (1986).
Maeda et al., "Construction of reshaped human antibodies with HIV-neutralizing activity," Hum. Antibod. Hybrid., 2:124-134 (1991).
Morrison et al., "Chimeric human antibody molecules: Mouse antigent binding-domains with human constant region domains," Proc. Natl. Acad. Sci., 81:6851-6859 (1984).
Morrison, S.L., "Transfectomas Provide Novel Chimeric Antibodies," Science, 229:1202-1207 (1985).
Neuberger et al., "A hapten-specific chimeric IgE antibody with human physiological effector function," Nature, 314:268-270 (1985).
Riechmann et al., "Reshaping human antibodies for therapy," Nature, 332:323-327 (1988).
Sahagan et al., "A Genetically Engineered Murine/Human Chimeric Antibody Retains Specificity for Human Tumor-Associated Antigen," J. Immunol., 137:1066-1074 (1986).
Verhoeyen et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," Science, 239:1534-1536 (1988).
Amit et al., Science, 233, 747-753 (1986).
Cheetham, Protein Engineering, 2(3), 170-172 (1988).
Chothia et al., J. Mol. Biol., 186, 651-663 (1985).
Chothia et al., Nature, 342, 877-883 (1989).
Chothia et al., Science, 233, 755-758 (1986).
Chothia and Lesk, EMBO J., 5, 823-826 (1986).
Colman et al., Nature, 326, 358-362 (1987).
Davies et al., Ann. Rev. Immunol., 1, 87-117 (1983).
Davies et al., J. Biol. Chem., 263(22), 10541-10544 (1988).
Epp et al., Eur. J. Biochem., 45, 513-524 (1974).
Feldmann et al., Mol. Immunol., 18, 683-698 (1981).
Kabat, J. Immunol., 125, 961-969 (1980).
Lesk and Chothia, J. Mol. Biol., 160, 325-342 (1982).
Padlan, Mol. Immunol., 31, 169-217 (1994).
Palm et al., Hoppe Seyler's Z. Physiol. Chem., 354(12), 1651-1654 (1973).
Palm et al., Hoppe Seyler's Z. Physiol. Chem., 356, 167-191 (1975).
Panka et al., PNAS-USA, 85, 3080-3084 (1988).
Roberts et al., Nature, 328, 731-734 (1987).
Saul et al., J. Biol. Chem., 253(2), 585-597 (1978).
Sheriff et al., PNAS-USA, 84, 8075-8079 (1987).
Stanford and Wu, J. Theor. Biol., 88, 421-439 (1981).
Tramontano et al., J. Mol. Biol., 215, 175-182 (1990).
Verhoeyen et al., BioEssays, 8(2), 74-78 (1988).
Waldmann et al., Cancer Research, 45, 4559s-4562s (1985).
Wu and Kabat, J. Exp. Med., 132, 211-250 (1970).
Better et al. "Escherichia coli Secretion of an Active Chimeric Antibody Fragment," Science, 240:1041-1043 (1988).
Bird et al., "Single-Chain Antigen-Binding Proteins," Science, 242:423-426 (1988).
Boulianne et al., "Production of functional chimeric mouse/human antibody," Nature, 312:643-646 (1984).
Carter et al., "Humanization of an anti-p185.sup.HER2 antibody for human cancer therapy," Proc. Natl. Acad. Sci., 89:4285-4289 (1992).
Co et al., "Humanized antibodies for antiviral therapy," Proc. Natl. Acad. Sci., 88:2869-2873 (1991).
Co et al., "Chimeric and humanized antibodies with specificity for the CD33 antigen," J. Immunol., 148:1149-1154 (1992).
Daugherty et al., "Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expansion of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins," Nuc. Acids. Res., 19:2471-2476 (1991).
Ellison et al., "The nucleotide sequence of a human immunoglobulin c(gamma).sub.1 gene," Nucleic Acids Res., 10:4071-(1982).
Farrar, J., "The biochemistry, biology, and the role of interleukin-2 in the induction of cytotoxic T cell and antibody-forming B cell receptors," Immunol. Rev., 63:129-166 (1982).
Foote et al., "Antibody framework residues affecting the conformation of hypervariable loops," J. Mol. Biol., 224:487-499 (1992).
Gorman et al., "Reshaping a therapeutic CD4 antibody," Proc. Natl. Acad. Sci., 88:4181-4185 (1991).
Greene et al., "Growth of Human T Lymphocytes: An Analysis of Interleukin 2 and its Cellular receptor," Progress in Hematology XIV, E. Brown, ed., Grune and Statton, New York, pp. 283-301 (1986).
Hale et al., "Remission Induction in Non-Hodgkin Lymphoma with Reshaped Human Monoclonal Antibody CAMPATH-1H," Lancet, Dec. 17, 1988, pp. 1394-1399.
Hieter et al., "Cloned Human and Mouse Kappa Immunoglobulin Constant and J. Region Genes Conserve Homology in Functional Segments," Cell, 22:197-207 (1980).
Huston et al., "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli," Proc. Nat. Acad. Sci. USA, 85:5879-5883 (1988), Progress in Hematology XIV, E. Brown, ed., Grune and Statton, New York, p. 283, (1986).
Kettleborough et al., "Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation," Protein Eng., 4:773-783 (1991).
Kirkman et al., J. Exp. Med., 162:358 (1985).
Leonard et al., "The human receptor for T-cell growth factor," J. Biol. Chem., 260:1872-1880 (1985).
Liu et al., "Expression of mouse::human immunoglobulin heavy-chain cDNA in lymphoid cells," Gene, 54:33-40 (1987).
Queen et al., "A humanized antibody that binds to the interleukin 2 receptor," Proc. Natl. Acad. Sci., 86:10029-10033 (1989).
Routledge et al., "A humanized monovalent CD3 antibody which can activate homologous complement," Eur. J. Immunol., 21:2717-2725 (1991).
Shalaby et al., "Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene," J. Exp. Med., 175:217-225 (1992).
Sharon et al., "Expression of a V.sub.H C.sub.K chimaeric protein in mouse myeloma cells," Nature, 309:364-367 (1984).
Shearman et al., "Construction, expression and characterization of humanized antibodies directed against the human .alpha./.beta. T cell receptor," J. Immunol., 147:4366-4373 (1991).
Takeda et al., "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences," Nature, 314:452-454 (1985).
Tan et al., "A Human-Mouse Chimeric Immunoglobulin Gene with a Human Variable Region is Expressed in Mouse Myeloma Cells," J. Immunol., 135:3564-3567 (1985).
Tempest et al., "Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo," Bio/Technology, 9:26-271 (1991).
Uchiyama et al., "A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T-cells," J. Immunol., 126:1393-1397 (1981).
Vitt
Co Man Sung
Coelingh Kathleen L.
Landolfi Nicholas F.
Queen Cary L.
Schneider William P.
Feisee Lila
Protein Design Labs, Inc.
Reeves Julie E.
LandOfFree
Humanized immunoglobulins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Humanized immunoglobulins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Humanized immunoglobulins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-802629